According to a Lancet study, ariptadil does not enhance clinical outcomes in COVID-19 patients who have acute hypoxaemic respiratory failure.

Published Date: 23 Jun 2023

USA: Patients with acute hypoxemic respiratory disease associated with COVID-19 did not respond better to intravenous aviptadil up to day 90.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.

2.

GuCS: Genitourinary Cancers Symposium

3.

Obesity-associated cancers tripled nationwide over past two decades

4.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

5.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot